Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C from birth to adulthood.

Vincenzo Serretta1, Cristina Scalici Gesolfo1, Vincenza Alonge1

  • 1Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy.

Urologia
|October 8, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Oncological Outcomes in Patients with Multiple PiRADS Lesion Treated with Robot-Assisted Radical Prostatectomy for Prostate Cancer: Results from a Large Contemporary Cohort with Centralized MpMRI Evaluation in a High-Volume Center.

Journal of clinical medicine·2026
Same author

When Perinephric Fat Tells a Deeper Story: Rethinking Risk After Radical Nephrectomy.

Mayo Clinic proceedings·2026
Same author

Anatomical distribution and predictors of lymph node metastasis in robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: a multicenter study by the Junior ERUS/YAU Robotic Surgery Working Group.

World journal of urology·2026
Same author

Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.

Oncology research·2026
Same author

Safe to Spare? Predictors of Oncological Safety for Nerve-Sparing Technique during Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer. Insight from a High Volume Center with Centralized mpMRI Review.

International braz j urol : official journal of the Brazilian Society of Urology·2026
Same author

The Evolving Role of Artificial Intelligence in Andrological Surgery: Current Landscape and Future Direction.

Journal of clinical medicine·2026
Same journal

The current standing of standard PCNL in the era of miniaturization.

Urologia·2026
Same journal

Thanks to Reviewers.

Urologia·2026
Same journal

Cutaneous ureterostomy versus ileal conduit as urinary diversion in patients with muscle-invasive bladder cancer undergoing radical cystectomy: A comparative analysis of high-risk cases.

Urologia·2026
Same journal

Do we have to do ureteric reimplantation during augmentation cystoplasty in patients with spastic neurogenic bladder?

Urologia·2026
Same journal

Multiomics empowers predictive drug resistance in advanced prostate cancer.

Urologia·2026
Same journal

Spectrum of genital findings in ART-conceived male neonates: A blinded case series analyzing parental reproductive history.

Urologia·2026
See all related articles

Mitomycin C (MMC) intravesical therapy effectively treats superficial bladder tumors and prevents recurrence. Despite proven efficacy and low toxicity, urologists should optimize its adoption in clinical practice.

Area of Science:

  • Uro-oncology
  • Pharmacology
  • Clinical Urology

Background:

  • Mitomycin C (MMC) intravesical therapy for superficial bladder tumors was introduced in the 1970s.
  • Pharmacokinetic studies have optimized its administration and confirmed its efficacy and low toxicity.

Purpose of the Study:

  • To review the established role of intravesical Mitomycin C in bladder cancer treatment.
  • To highlight its efficacy in ablative and prophylactic settings.
  • To discuss its place alongside Bacillus Calmette-Guerin (BCG) in current guidelines.

Main Methods:

  • Review of pharmacokinetic studies.
  • Analysis of randomized trials and meta-analyses.
  • Examination of European Association of Urology (EAU) guidelines.

Related Experiment Videos

Main Results:

  • Intravesical MMC demonstrated significant complete response rates (e.g., 42% in one study).
  • Numerous studies confirmed its benefit in prophylaxis versus transurethral resection (TUR) alone.
  • Meta-analyses and EAU guidelines support its role in adjuvant chemotherapy and early instillation to prevent recurrence.

Conclusions:

  • Intravesical MMC is effective for superficial bladder tumors and recurrence prevention.
  • While BCG is preferred for high-risk cases, MMC is suitable for low-risk and can be used for intermediate-risk patients.
  • Further efforts are needed to fully integrate immediate intravesical MMC into common clinical practice.